PDCD1 and small cell lung carcinoma: To further deduce whether SCLC tumors with different immune properties would be associated with different immune checkpoint blockade (ICB) responses, we performed targeted gene expression analysis of 14 samples from SCLC patients who received anti-PD-1 treatment.